Outer retinal degeneration is the leading cause of blindness in the developed world. A new study now demonstrates that ectopic expression of human rhodopsin in the inner retina, mediated by viral gene therapy, can restore light sensitivity and some vision to mice blind from outer retinal degeneration.
Blindness remains a major public health challenge. Worldwide, 285 million people are visually impaired, and about 39 million legally blind [1] . In the developed world, the leading causes of acquired and hereditary blindess -age-related macular degeneration and retinitis pigmentosa, respectively -both share a common pathophysiology. In each, the rod and cone photoreceptors of the outer retina undergo irreversible degeneration ( Figure 1A ,B). While the inner retina remains largely intact, in the absence of outer retinal phototransduction no visual information can be transmitted from the retinal ganglion cells to the brain. In this issue of Current Biology, Cehajic-Kapetanovic and colleagues [2] show that virally mediated gene therapy of human rhodopsin, expressed in the surviving cells of the inner retina, can restore vision-like physiology and behavior to mice blind from outer retinal degeneration.
A number of approaches to restore vision by conferring light sensitivity to the remaining inner retinal cells have been pursued in the past decade. Approaches that have shown promise include use of gene therapy with microbial opsins such as Chlamydomonas channelopsin to introduce light-regulated ion channels to inner retinal cells [3] [4] [5] ; gene therapy to introduce the non-visual pigment melanopsin to the inner retina [6] ; one-component and two-component optochemical photoswitches, which utilize light-isomerizable channel agonists to confer light sensitivity to remaining inner retinal photoreceptors [7] [8] [9] ; and opto-electronic prostheses that stimulate retinal ganglion cells directly [10] . The latter approach is now approved in the US for clinical use. While these methods have all resulted in reconstituted light-dependent firing of optic nerve fibers and restored behavioral responses to light, each has a number of potential limitations. Use of channelopsins incurs risks inherent in expressing foreign proteins chronically in the retina, and lack of signal amplification necessitates relatively bright light for function. Relative to native rod and cone opsins, melanopsin has slow kinetics and relatively low sensitivity, which would likely limit acuity. One-component photoswitches lack cell-type specificity while two-component photoswitches require both gene therapy and a chemical adjunct, which may limit practical application. And opto-electronic approaches are limited by the physics of external stimulation of cells with resultant low spatial resolution.
Ideally, a photopigment used to restore visual functions via inner retinal expression should be very light-sensitive, have strong signal amplification, be native to the organism, and be expressible in the remaining cells of the degenerated retina. Gene therapy with rhodopsin would seem to fit these requirements. However, a priori, rhodopsin would seem to be a poor candidate, as its photocycle is intrinsically tied to the G-protein transducin (which is not expressed at high levels in the retina outside the photoreceptors), and requires continual chromophore replenishment from the retinal pigment epithelium (RPE) through a mechanism thought to be Current Biology 25, R711-R731, August 17, 2015 ª2015 Elsevier Ltd All rights reserved R713 Current Biology Dispatches closely tied to the physical interaction between photoreceptors and RPE.
It is thus remarkable that CehajicKapetanovic et al. [2] succeeded with this approach. The group used the rd1 mutant mouse as their model. These mice carry a mutation in the phosphodiesterase 6b gene which results in nearly complete outer retinal degeneration by 3 months of age (and is essentially similar to certain forms of human retinitis pigmentosa [11] ). The researchers generated two adenovirus-associated viral (AAV) gene therapy vectors, each expressing human rhodopsin cDNA under the control of a different promoter. The first version, using the CAG hybrid cytomegalovirus-chicken actin promoter, expressed rhodopsin ubiquitously throughout the remaining inner retinal cells of rd1 mutant mice ( Figure 1C ). In the second version, the group expressed human rhodopsin under control of the grm6 promoter, which resulted in expression primarily in ON bipolar interneurons (which normally sit between the photoreceptors and retinal ganglion cells comprising the optic nerve) ( Figure 1D ).
To demonstrate restoration of light-responsiveness, the authors first LGN responses and behavioral avoidance responses to the movie. Taken together, these results strongly suggest that some visual function was restored to these blind animals by the gene therapy, particularly for the animals treated with the grm6 vector. While the restoration of some visual function by this approach is a truly remarkable achievement, a number of questions still remain in considering translation of this approach to the treatment of human blindness. The latencies exhibited by retinal ganglion cells after brief light pulses were quite broad, which might portend low temporal resolution of vision ultimately. The authors did not stress this system with very bright light, which might be expected to bleach rhodopsin (particularly in eyes with poor retinal pigment epithelial function, which is often the case clinically in patients with photoreceptor degeneration). Of note, for in vitro recordings, exogenous retinaldehyde chromophore was required to maintain sensitivity. While the ONbipolar pathway has been shown to be necessary for normal human vision [12] , its sufficiency for creating visual information is unclear. Normal vision occurs over a remarkable range of intensities and contrast levels, which is made possible by multiple light adaptation mechanisms [13] . It is unclear which if any adaptation mechanisms will be functional in the rescued retina. This work also raises some fascinating physiology questions. While rhodopsin has been known to be a promiscuous G-protein coupled receptor [14, 15] , its efficiency in signal transduction in the bipolar and other inner retinal cells is remarkable. What G-protein is mediating these effects, and will there be compensatory changes in its signaling with chronic expression of the receptor? How is the rhodopsin photocycle mediated in these animals? Normally the close apposition of rods and RPE is thought to be important for the chromophore photocycle [16] ; is the RPE responsible for the recycling of chromophore in these degenerated animals as well? If so, will utility of this approach be limited in patients with RPE dysfunction such as in atrophic macular degeneration?
The current work is similar in concept to the recent description of rescue of visual function in the rd1 mouse using a chimeric melanopsin/mGluR6 metabotropic glutamate receptor gene therapy construct [17] . Similar to the current work, this protein was driven by the grm6 promoter in ON-bipolar cells using an AAV viral vector. Interestingly, similar to rhodopsin, this construct also restored light responses to blind retinas with a range of latencies, although the sensitivity of responses using the chimeric protein appeared to be about one log less than for the rhodopsin-AAV construct. However, the measured visual acuity (using optokinetic reflex testing) of melanopsin/ mGluR6-rescued rd1 mice was about 0.15 cycle/degree, higher than that described in the current work for rhodopsin (with the caveat that different tests for visual acuity were employed in the two studies).
The demonstration of rescue of visual function by rhodopsin and chimeric G-protein coupled receptor gene therapies targeted at ON-bipolar cells are milestones in efforts to reverse blindness. The natural advantages of using native proteins with intrinsic signal amplification will immediately make this an attractive approach for translation to clinical use. As gene therapy in the retina appears to be safe and efficacious (as demonstrated by clinical trials with AAV-mediated expression of RPE65 for Leber congenial amaurosis [18, 19] ), the path to clinical translation for rhodopsin and similar therapies is clear.
